Table 2 Concentrations of pneumococcal polysaccharide antigen serotype-specific IgG antibodies and opsonization indices in the rheumatoid arthritis treatment groups before and after 23-valent pneumococcal polysaccharide vaccination

IgG GMCs, μg/ml

6B

Before

0.84 (0.58 to 1.11)

1.42 (0.86 to 1.97)

1.61 (1.11 to 2.11)

NS

After

4.05 (2.13 to 5.97)*

4.36 (2.17 to 6.55)*

8.35 (2.79 to 13.91)*

NS

Fold increase

2.38 (1.41 to 5.62)

1.75 (1.15 to 3.11)

2.04 (1.71 to 5.76)

NS

23F

Before

1.17 (0.85 to 1.48)

1.79 (1.33 to 2.25)

1.38 (0.68 to 2.08)

NS

After

11.61 (4.16 to 19.07)*

7.41 (4.48 to 10.33)*

16.73 (7.81 to 25.65)*

NS

Fold increase

3.36 (1.85 to 9.42)

2.00 (1.27 to 5.48)

7.63 (3.70 to 18.85)

0.005 (MTX vs. TAC)

GM-OIs

6B

Before

17.24 (10.96 to 23.53)

150.79 (14.85 to 286.74)

262.89 (56.54 to 469.25)

NS

After

981.15 (407.24 to 1555.05)*

584.29 (270.29 to 898.28)*

2026.54 (1047.56 to 3005.51)*

0.002 (MTX vs. TAC)

Fold increase

10.22 (1.92 to 79.48)

2.57 (1.22 to 22.40)

20.80 (3.86 to 70.38)

NS

23F

Before

63.21 (−6.79 to 133.20)

52.11 (14.04 to 90.18)

164.57 (−129.84 to 458.98)

NS

After

713.49 (307.97 to 1119.01)*

724.56 (336.93 to 1112.19)*

1583.04 (773.21 to 2392.86)*

0.013 (MTX vs. TAC)

Fold increase

6.86 (2.50 to 27.14)

3.75 (1.47 to 38.32)

64.38 (11.59 to 231.22)

0.048 (MTX vs. TAC)